


MIMIVA SurVaxM Update

Mike Ciesielski, PhD CEO, MimiVax, Inc.


mciesielski@mimivax.com www.mimivax.com

MimiVax History



MIMIVA

MimiVax: Pipeline






Survivin as a target

• Survivin is:

An over-expressed Pan-Cancer target

- An Onco-fetal protein, typically turned on during fetal development
- Rarely expressed in adult tissues
- 7 distinct protein isoforms

Cytoplasmic, Nuclear, Mitochondrial & Cell-Surface expression patterns



N





SurVaxM Vaccine

SurVaxM is:

An off-the-shelf immunotherapeutic

Targeted to a key structural epitope of survivin

Modified to enhance its immunogenicity

SurVaxM's MOA is:

Both IgG & T-Cell immunemediated attack

Potential for biological interference by IgG





- 15 AA Structurally-Altered Synthetic Long Peptide (SLP)
 - Conjugated to highly immunogenic Keyhole Limpet Hemocyanin (KLH)
- Adjuvanted with Montanide & Local GM-CSF (sargramostim)
- Dosage: 500µg SurVaxM in Montanide ISA51 VG + 100µg GM-CSF
- Delivered as a Subcutaneous Injection
- 4 initial biweekly doses (q2week x 4)
- Ongoing maintenance dosage once every 2 months (q2month)




• CD4⁺ & CD8⁺ T-Cells target intra-cellular survivin via MHC-associated epitope presentation

.





Immune Response




MIMIVA

6

SurVaxM targets a conserved region of survivin present in several survivin-family isoforms


• Survivin has several isoforms, with different functions & cellular localization.



Clinical Data

Phase 2a in newly diagnosed GBM 2024 Update

Survival Data – Measured from <u>Diagnosis</u>



SurVaxM: Phase 2a Study of SurVaxM in adult nGBM (NCT02455557)

PHASE 2a Single Arm DESIGN:

NEWLY DIAGANOSED GLIOBLASTOMA (*n*=63)

Gross total resection (≤ 1cm³) & completed initial Standard of Care therapy

Enrolled at:



SurVaxM (Single Arm)

SurVaxM in emulsion with Montanide Sargramostim (local injection)

Combined with Standard TMZ

• Dosing q2w x 4 doses and then q2m until tumor progression or unacceptable toxicity occurs.


ENDPOINTS:

1°	Prog	gressio	n Free Surv	ival (+)
	_			

- 2° Overall Survival
- 3° Immune Response & (+) Biomarker Analysis (DNA/RNA)
 - Enrolled: 2015-2020
 - Published: JCO 2023
 - Ongoing Updates...



Phase 2a Study of SurVaxM in nGBM: Schedule & Demographics




MIMIVA

12 (19.0%)

≥20%

10

Phase 2a Study of SurVaxM in nGBM (2024) (All patients, measured from diagnosis, N=63)



MIMIVA

11

Phase 2a Study of SurVaxM in nGBM: Safety

Preferred term	Grade 1	Grade 2	Grade 3	Grade 4	Preferred term	Grade 1	Grade 2	Grade 3	Grade 4
Alopecia	1/1 (1.6%)				Lymphopenia	2/2 (3.1%)	6/6 (9.4%)	1/1 (1.6%)	1/1 (1.6%)
Amnesia	2/2 (3.1%)				Malaise	2/2 (3.1%)			
Arthralgia	3/3 (4.7%)				Myalgia	4/4 (6.3%)	1/1 (1.6%)		
Asthenia		1/1 (1.6%)			Nausea	1/1 (1.6%)			
Back Pain	1/1 (1.6%)				Neutrophil count	2/2 (3.1%)	2/2 (3.1%)		1/1 (1.6%)
Chills	1/1 (1.6%)				decreased	2/2 (3:170)			1/1 (1.070)
Confusion			1/1 (1.6%)		Panniculitis		2/2 (3.1%)		
Decreased appetite	1/1 (1.6%)	1/1 (1.6%)			Paresthesia	3/3 (4.7%)			
Fatigue	12/12 (18.8%)	1/1 (1.6%)			Platelet count decreased	2/2 (3.1%)			
Hyperhidrosis	1/1 (1.6%)				Pruritus	2/2 (3.1%)	1/1 (1.6%)		
Hypersensitivity					Pyrexia	2/2 (3.1%)			
Hypertension - aggravated		1/1 (1.6%)			Rash	2/2 (3.1%)	1/1 (1.6%)	1/1 (1.6%)	
Influenza-like illness	7/3 (4.7%)				Rash maculo-papular			1/1 (1.6%)	
Injection site haematoma	5/4 (6.3%)				Skin hypertrophy	1/1 (1.6%)			
Injection site induration	5/3 (4.7%)				Subcutaneous nodule	3/3 (4.7%)			
Injection site pain	12/9 (14%)				Transaminases increased		1/1 (1.6%)		
Injection site pruritus	2/2 (3.1%)				Urticaria	1/1 (1.6%)	1/1 (1.6%)		
Injection site reaction	37/24 (37.5%)	3/3 (4.7%)			Leukopenia	4/4 (6.3%)			
Injection site swelling	2/2 (3.1%)				***AE's are inclusive of t	hose attributab	ole to temozo	lomide	

31

MIMIVA

Phase 2a Study of SurVaxM in nGBM: IgG Response Correlates with OS

100,000

90,000

80,000

70,000-

60,000-

50,000

40,000

30,000-

20,000

10,000-

Baseline (Pre-Imm.)

Survivin-Specific Antibody Titer (IgG)


Significantly higher All Pts., Lo IgG (< 30,000)-OS associated with P=0.0146 high titer IgG All Pts., Hi IgG (> 30,000)responses meMGMT, IDH1wt + mut, Lo IgGmeMGMT, IDH1wt + mut, Hi IgG-Stratification by • IDH1 and MGMT all unMGMT, IDH1wt + mut, Lo IgGtrend to better OS unMGMT, IDH1wt + mut, Hi IgGwith higher titer IgG meMGMT, IDH1wt only, Lo IgGmeMGMT, IDH1wt only, Hi IgGunMGMT, IDH1wt only, Lo IgGunMGMT, IDH1wt only, Hi IgG-0.1 10 Hazard Ratio (95% CI) **V**5 V6 V7 Post-V4


MIMIVA


Ahluwalia, MS, Reardon, DA, Abad, AP et al. Phase 2a Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma. J Clin Oncol 41(7) 1453-1465 (2023).

Biomarker Response from Phase 2a Study

 \uparrow Antibody (IgG) Response = \uparrow OS & PFS (P=0.0146)








76% of patients had IgG > 30,000

³³ MIMIVA

Phase 2a Study of SurVaxM in nGBM: T-Cell Response



Ahluwalia, MS, Reardon, DA, Abad, AP et al. Phase 2a Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma. J Clin Oncol 41(7) 1453-1465 (2023).

34

MIMIVA

SUR W/IN

Phase 2b Study of SurVaxM in nGBM (SURVIVE)

Prospective Randomized Placebo-Controlled Trial of SurVaxM for Newly Diagnosed Glioblastoma (NCT0516308)

PHASE 2b RCT DESIGN:

NEWLY DIAGANOSED GLIOBLASTOMA (n=270)

Gross total resection (≤ 1cm³) & completed initial Standard of Care therapy (Same as Phase 2a)

Stratified for MGMT methylation & IDH1 status



RANDOMIZED 3:2

SurVaxM (Arm A) SurVaxM in emulsion with Montanide Sargramostim (local injection) Standard-of-care TMZ

Placebo (Arm B) Saline in emulsion with Montanide Saline (local injection) Standard-of-care TMZ

• Dosing q2w x 4 doses and then q2m until tumor progression or unacceptable toxicity occurs.

ENDPOINTS:

- 1° Overall Survival:
 - OS12 (surrogate)
 - mOS (confirmatory)
- 2° Progression Free Survival:• mPFS
 - 1^{rst} per Central Imaging (RANO)

MIM

- 2nd per PI
- 3° Immune Response & Biomarker Analysis (DNA/RNA)


Recently Featured in National Media

A& NEWS

WATCH NOW 8

Experimental vaccine shows promise in delaying the return of aggressive brain tumor

The vaccine, called SurVaxM, was shown to nearly double the survival time in a trial of 63 patients. Researchers now hope to confirm the findings in a larger trial.



— An experimental brain tumor vaccine targets a protein found in tumors called survivin that's thought to play a role in the survival of cancer cells. Allie Sullberg for NBC News

f 🎔 🗠 📼 🗌 🗔 SAVE

June 12, 2023, 5:00 AM EDT

By Berkeley Lovelace Jr.











ATY SANCHEZ DEFYING GLIOBLASTOMA PROGNOSIS THROUGH CLINICAL TRIA



PROMISING SIGNS FROM EXPERIMENTAL CANCER VACCINE



Paily EXPERIMENTAL VACCINE SHOWS PROMISING RESULTS SLOWING GROWTH OF DEADLY BRAIN CANCER





MimiVax: Timeline

Randomized Phase 2b trial launched 2022

FDA Fast-Track Designation 9/2023

FDA Expanded Orphan Designation 5/2024 Phase 2b SURVIVE (newly diag. GBM) Interim Analysis 8/2024

Seeking Partnership, Licensing, M&A, IPO

45

Continue as 2b or Convert to 3

Accelerate other Cancer Indications for SurVaxM (Multiple Myeloma, Lung Cancer, Pediatric Brain Cancer)

Pre-Clinical Development of Survivin Antibodies

Oncology & Autoimmune Indications

Independent US Market Analysis: SurVaxM ranks #2 for a predicted \$254M US market share

Parameters	Efficacy	Safety	Entry Order	Return on Asset	Weighted Score	Rank	Phase	Company	Mkt Cap	Share	Market Share Prediction
Scores					-						
1 st Line Drug											\$2.8B Total
DCVax	9	9	10	7.5	8.9	1	phase 3 (single arm)	Northwest Bio	\$648M	\$0.60	\$271.1
SurVaxM	9	9	7	9	8.7	2	phase 2b RCT	MimiVax	\$120M	Private	\$254.7
INO-5401	8.5	8.5	7	8	8.2	3	phase 1/2	Inovio	\$116M	\$0.45	\$152.5
VAL-083	8	8	8	8	8.0	4	phase 1	Kintara	\$5.4M	\$3.23	\$157
Enzastaurin	8	8	7	8	7.9	5	phase 1/2	Denovo	\$45M	Private	\$133.7
Paxalisib	7.5	8	8	8	7.8	6	phase 2 (single arm)	Kazia	\$28M	\$1.23	\$152.2
Temferon	7.5	8	6	8.5	7.6	7	phase 1/2	Genenta	\$108M	\$5.97	\$123.4
AV-GBM-1	7	8	6	8.5	7.4	8	phase 2 (single arm)	Avita	\$610M	\$4.65	\$103.2
TV1-Brain-1	6 - ght-marke	6	20227	8.5	6.5	9	phase 1	TVAX	\$50M	Private	\$66.9
LAM561 (2-OHOA)	-gnt-marke 5	t research 5	2023	8	6.1	10	phase 1/2	Laminar	\$5M F	Private	\$176.5
ITI-1000 (pp65 DC Vaccine)	5	5	7	7.5	5.7	11	phase 1	Immunomics	\$64M	Private	\$88.6



			Market	Capture Per Year
Glioblastoma	Cases/yr	24% (Low)	40% (Average)	 With low market penetrance (24%) SurVaxM is \$310.0M GBM market per year in the US alone
USA	13,000	\$0.31	\$0.52	
China	70,000	\$1.68	\$2.80	 COGS SurVaxM expected to be \$300/single dose base manufacture cost
Japan	2,700	\$0.06	\$0.11	 Estimated Pricing
Korea	627	\$0.02	\$0.03	potentially \$100,000/8 dose regimen/yr.
France	3,200	\$0.08	\$0.13	 Comparatively a course of temozolomide chemotherapy
Germany	4,700	\$0.11	\$0.19	currently used for all GBM patients (SOC) is \$120,000/yr. and represents a \$600M GBM market/yr.
Italy	4,300	\$0.10	\$0.17	
Spain	2,600	\$0.06	\$0.10	 In contrast to cellular-based immune therapies (DC, CART) which average >\$200,000/dose and are close to
UK	2,800	\$0.07	\$0.11	\$1M per course/per patient. Cellular immunotherapy is
	Billions	\$\$\$2.49	\$4.16	very difficult for insurance reimbursement and market sustainability.

Sources:

Annual Report to the Nation on the Status of Cancer, 1999-2015 JNCI: Journal of the National Cancer Institute, 2019 1.

Chin Med J (Engl). 2011 124(17):2578-83., Datamonitor Healthcare 2.

Brain Tumor Res Treat. 2017 5(1):16-23. 4.



Global, regional, and national burden of brain and other CNS cancer, 1990-2016: a systematic analysis for the Global Burden of 3. Disease Study 2016



Glioblastor

SurVaxM

Data Driven

150 BIASTO

Unique MOA

Antibody

28.1 mos. mOS 14.4 mos. mPFS

Response

1 Clin Oncol 2022 Dec 15; CO2200996

MIMIVA





MICHAEL CIESIELSKI, PHD CEO & co-founder

ROBERT FENSTERMAKER, MD СМО

& co-founder



SCOTT FRIEDMAN

Board Member & co-founder (Partner, Lippes Mathias, LLP)



Board Chair







JERRY JACOBS, JR ROD THOMPSON, PHD DAVE MALLIAROS, PHD

> Acting Head, CMC (BioPharm Process Assoc., LLC)

Acting Head, QA (Syner-G BioPharma Group)

Regulatory (VP, Translational Medicine, TD2)

JENNY KEPPLER, MBA



MANMEET AHLUWALIA, MD Scientific Advisory Board CSO & Deputy Director, Miami Cancer Institute



DANIELLE CASUCCI

BA, BS, GN, CCRP, CCIP

VP. Clinical

Operations

ELAD LEVY, MD Scientific Advisory Board Chair, Neurosurgery, University at Buffalo



HENRY KAMINSKI, MD

Scientific Advisory board Chair, Neurology,



LINDA KUSNER, PHD

Scientific Advisory board Res. Prof. Pharmacol. & Physiol. George Washington University George Washington University



DAVID HOHN, MD

Board Member President & CEO Emeritus. **Roswell Park**



Board Member

SVP & Chief Legal Officer,

Roswell Park

MICHAEL SEXTON



Board Observer Mng. Dir., Sontag innovation Fund

WORKING TOGETHER WITH EXPERIENCED CRO'S



PROUDLY SUPPORTED BY PRIVATE INVESTORS, VENTURE PHILANTHROPY, DONATIONS & THE BUFFALO, NY COMMUNITY



(CEO, Delaware North)

MimiVax:Updates

MimiVax was granted Fast-Track Designation Approval by US FDA for SurVaxM on 9/22/2023



Our Reference: IND 27050

GRANT FAST TRACK DESIGNATION September 22, 2023

MimiVax, LLC Attention: Nick Martinez Translational Drug Development (TD2) 13208 E. Shea Blvd. Suite 100 Scottsdale, AZ 85259

Dear Mr. Martinez:

Please refer to your Investigational New Drug Application (IND) submitted under section 505(i) of the Federal Food, Drug, and Cosmetic Act (FDCA) for "SVN53-67/M57-KLH Vaccine (SurVaxM), administered with Temozolomide."

We also refer to your request for fast track designation received August 11, 2023, submitted under section 506(b) of the FDCA. We have reviewed your request and have determined that SVN53-67/M57-KLH Vaccine (SurVaxM) in combination with standard of care for the treatment of patients with newly diagnosed glioblastoma multiforme (GBM) to improve overall survival meets the criteria for fast track designation. Therefore, we are granting your request for fast track designation. Please note that if the drug development program does not continue to meet the criteria for fast track designation, we may rescind the designation.


For further information regarding fast track drug development programs, please refer to the guidance for industry *Expedited Programs for Serious Conditions – Drugs and Biologics* at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/UCM358301.pdf.

Additional Data



MV2C2 Antibody Program

Myasthenia Gravis





Humanized MV2C2 Program

Murine MV2C2-IgG2b (prototype)

Humanized MV2C2-IgG1 (Lead candidate)




NIH-NINDS-SBIR Supported

- Lead human antibody slated for Ph 2 SBIR application, IND enabling for auto-immune disease (Myasthenia Gravis)
- sdAb second generation survivin targeting binders/SurVaxM agents in oncology (tissue penetrating & ADC options)
- Seeking development and/or acquisition partners for antibody platform program




SurVaxM anti-tumor humoral and cellular response

- The anti-survivin antibody (MV2C2) used SurVaxM as the antigen to recapitulate what we see in patients for further study
- GL261 glioma cell model growing SQ in C57Bl/6 mice
- Adoptively transferred PBMC from SurVaxM immunized to naïve mice retains some anti-tumor activity
- Transferred SurVaxM antisera also retains some antitumor activity in naïve mice
- Purified murine mAb IgG exhibits potent anti-tumor activity by itself <u>without</u> any T cells
 - Survivin isoforms are present at the cell surface, accessible to antibody-mediated immune mechanisms






Anti-SurVaxM derived mAb IgG: ? H\$5\$ Pre-clinical studies: Melanoma & Glioma



 Cloned anti-SurVaxM antibodies control tumor growth in SQ models of glioma(GL261) & melanoma (B16)



• Also effective treating GL20 growing intracranially

MIMIVA

86

Total Survivin Expression MG Thymus




Figure 3. Survivin expression in the thymus. Representative images from an analysis of eleven thymuses from MG patients were analyzed for survivin expression (immunosuppression treated, n=7; immnosuppression naïve, n = 4).

A–D) MG thymus from a 24-year-old woman who had clinical symptoms for 2 years and an AChR antibody level of 19.3 nmol and had never received immunosuppression or prednisone showed a well developed cortex (C) and medulla (M), lymphofollicular hyperplasia with a germinal center (GC) close to Hassall's corpuscle (HC).

B,D) High number of survivin positive cells in the cortex (C), corticomedullary junction and the GC.


E–H) EOMG thymus from a AChR antibody positive 21-year-old female with lymphofollicular hyperplasia after long-term immunosuppression showing cortical atrophy and a slightly regressive germinal center (GC) close to a Hassall's corpuscle (HC).

F,H) Low number of survivin positive lymphocytes in the remnant cortical area (C), and the germinal center (GC) (A,B,E,F,6100; C,D,G,H6200).

doi:10.1371/journal.pone.0102231.g003



Survivin expression of B-cells (plasma lineage) in myasthenia gravis patients



Survivin expression in myasthenia gravis patients (1–15) and control (16–25) PBMCs. FACS analysis of total survivin expression of PBMC stained with antibodies to indicated markers. Data reflect the percentage of total cells staining positive.

MIMIN

Kusner L. L., Ciesielski M. J., Marx A., Kaminski H. J., Fenstermaker R. A. PLoS One 9: e102231. (2014)

Significance: mAb 2C2 reduces severity of Myasthenia Gravis in animal models

Experimental Autoimmune Myasthenia Gravis (EAMG) preclinical mouse model

